Welcome to our dedicated page for Lifevantage news (Ticker: LFVN), a resource for investors and traders seeking the latest updates and insights on Lifevantage stock.
LifeVantage Corporation reports developments for a health and wellness company built around nutrigenomics, dietary supplements, skin and hair care products, nootropic energy drink mixes, and pet supplements. Its product line includes Protandim, TrueScience Liquid Collagen, MindBody GLP-1 System, LoveBiome P84, AXIO, TrueScience skin and hair care products, and Petandim, sold through independent Consultants to customers.
Company news commonly covers quarterly results, regional sales trends, product innovation, patents tied to cellular-signaling supplement compositions, consultant events and training, international market expansion, executive leadership changes, share repurchases, and cash dividends. Updates also describe capital allocation and the company’s direct-selling business model.
LifeVantage (Nasdaq: LFVN) announced that Steve Fife, President and CEO, will retire in April 2026 after nine years at the company.
Fife will remain in his role during a transition while the Board conducts an extensive executive search and anticipates naming a new CEO in the coming months.
LifeVantage (Nasdaq: LFVN) reported Q2 fiscal 2026 results for the quarter ended Dec 31, 2025: revenue $48.9M (down 27.8% YoY, +2.9% sequential), net income $0.3M or $0.02 diluted, adjusted EPS $0.15, and adjusted EBITDA $3.9M. Gross margin was 74.0% with a $2.4M inventory obsolescence charge tied to MindBody GLP-1. Cash was $10.2M with no debt. The board approved a $60M share repurchase program and declared a $0.045 per-share cash dividend payable Mar 16, 2026. Fiscal 2026 guidance: revenue $185M–$200M; adjusted EBITDA $15M–$19M; adjusted EPS $0.60–$0.80.
LifeVantage (Nasdaq:LFVN) will release second quarter fiscal 2026 results for the quarter ended December 31, 2025 after market close on Wednesday, February 4, 2026. The company will host an investor conference call the same day at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) with U.S. dial-in (877) 704-4453 and international dial-in (201) 389-0920.
A telephone replay will be available about two hours after the call and accessible through Wednesday, February 18, 2026 via U.S. replay (844) 512-2921 or international (412) 317-6671 using confirmation code 13757766. A simultaneous live webcast will stream on the Investor Relations site and will be archived for approximately 30 days.
LifeVantage (Nasdaq: LFVN) held a virtual Global Kickoff on January 12, 2026, themed “Breakthrough,” uniting consultants worldwide and highlighting the LoveBiome integration.
Key announcements: launch of the Daily Activation mobile app for consultants and customers; the Activate90 Challenge running 12 weeks from the week of January 12 through April; and progress on the Healthy Edge wellness system.
Company-cited third-party in vitro data reported Healthy Edge activated 358 unique genes and a subset of 29 genes linked to cellular adaptability and stress resilience. Additional product rollouts are planned in 2026.
LifeVantage (Nasdaq: LFVN) announced on January 7, 2026 the appointment of Mike Edwards as Chief Technology Officer to lead the company’s digital transformation. Edwards brings more than 25 years of technology leadership with experience in eCommerce, artificial intelligence, CRM systems, mobile applications, and scaling global eCommerce infrastructure. The company said Edwards will focus on accelerating digital initiatives to streamline operations, enhance customer and Consultant experiences, and support global growth.
LifeVantage (Nasdaq: LFVN) will participate in the 28th Annual ICR Conference in Orlando, FL, January 12-14, 2026. CEO Steve Fife and CFO Carl Aure will present at approximately 1:00 p.m. ET on Monday, January 12, 2026. A live webcast of the presentation will be available on the company's Investor Relations News & Events page.
This provides investors and analysts access to company leadership commentary and a webcast replay option for those unable to attend live.
LifeVantage (Nasdaq: LFVN) announced that CEO Steve Fife and CFO Carl Aure will participate in a Water Tower Fireside Chat on Thursday, December 11, 2025. The live webcast will begin at approximately 2:00 p.m. ET and is open to all investors. Interested parties can register via the company's Investor Relations events page or the provided registration link.
This presentation offers investors a direct opportunity to hear management commentary and updates in a live Q&A-style format.
LifeVantage (Nasdaq: LFVN) announced in vitro results for its proprietary P84 formula on Nov 12, 2025 showing biologically meaningful effects on 14 gut peptides and proteins linked to regulation, repair, and restoration.
Key measured changes included GRP +1,087%, TFF3 +116%, VIP +100%, OXM +77%, and CCK +69%. The study used four gut cell types and reported that P84 exceeded typical biomarker thresholds (20–30%) across multiple targets. LifeVantage said it acquired LoveBiome assets in October 2025 and will next perform mRNA sequencing combining P84 with Protandim Nrf2 Synergizer and MindBody GLP-1 System.
LifeVantage (Nasdaq:LFVN) announced that its Board of Directors approved a quarterly cash dividend of $0.045 per share. The dividend will be paid on December 15, 2025 to shareholders of record at the close of business on December 1, 2025. This is a declared cash distribution to common stockholders approved by the company’s board.
LifeVantage (Nasdaq: LFVN) reported Q1 fiscal 2026 results for the quarter ended Sept 30, 2025, with revenue $47.6M (+0.7% YoY; +0.3% ex-FX). Gross profit was $37.8M (79.5% of revenue). Net income was $2.2M or $0.17 diluted; adjusted EPS was $0.18. Adjusted EBITDA was $3.9M. Cash and equivalents were $13.1M at Sept 30, 2025; no debt outstanding. The company closed the strategic acquisition of LoveBiome and repurchased 44,000 shares for ~$0.6M. A cash dividend of $0.045 per share was declared, payable Dec 15, 2025. Fiscal 2026 guidance reiterated: revenue $225–240M, adjusted EBITDA $23–26M, adjusted EPS $1.00–1.15.